Aviva Holdings’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Aviva Holdings’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,135,966	Closed	-$137M	–	4
2023 Q3	$137M	Hold	3,135,966	–	–	87.83%	1
2023 Q2	$113M	Hold	3,135,966	–	–	82.86%	1
2023 Q1	$117M	Hold	3,135,966	–	–	81.37%	1
2022 Q4	$142M	Hold	3,135,966	–	–	81.47%	1
2022 Q3	$219M	Hold	3,135,966	–	–	79.2%	1
2022 Q2	$211M	Hold	3,135,966	–	–	75.77%	1
2022 Q1	$258M	Hold	3,135,966	–	–	68.01%	1
2021 Q4	$460M	Hold	3,135,966	–	–	74.85%	1
2021 Q3	$555M	Hold	3,135,966	–	–	78.28%	1
2021 Q2	$507M	Hold	3,135,966	–	–	69.99%	1
2021 Q1	$537M	Hold	3,135,966	–	–	71.4%	1
2020 Q4	$689M	Hold	3,135,966	–	–	67.42%	1
2020 Q3	$521M	Hold	3,135,966	–	–	67.85%	1
2020 Q2	$358M	Hold	3,135,966	–	–	55.71%	1
2020 Q1	$241M	Buy	3,135,966 +275,000	+10%	+$24.7M	54.92%	1
2019 Q4	$369M	Sell	2,860,966 -275,000	-9%	-$26.5M	60.11%	1
2019 Q3	$244M	Hold	3,135,966	–	–	57.48%	1
2019 Q2	$323M	Hold	3,135,966	–	–	67.56%	1
2019 Q1	$230M	Hold	3,135,966	–	–	50.43%	1
2018 Q4	$133M	Hold	3,135,966	–	–	41.94%	1
2018 Q3	$148M	Hold	3,135,966	–	–	39.41%	1
2018 Q2	$155M	Hold	3,135,966	–	–	25.1%	2
2018 Q1	$96.3M	Hold	3,135,966	–	–	39.06%	2
2017 Q4	$57.2M	Buy	3,135,966 +255,264	+9%	+$3.96M	33.52%	2
2017 Q3	$33.7M	Hold	2,880,702	–	–	17.52%	2
2017 Q2	$10.5M	Hold	2,880,702	–	–	6.63%	3
2017 Q1	$15M	Buy	2,880,702 +888,617	+45%	+$4.87M	6.98%	2
2016 Q4	$9.46M	Hold	1,992,085	–	–	9.13%	2
2016 Q3	$13.2M	Hold	1,992,085	–	–	100%	1
2016 Q2	$10.9M	Buy	1,992,085 +446,084	+29%	+$7.11M	8.55%	2
2016 Q1	$33.3M	Buy	1,546,001 +1,023,501	+196%	+$22.9M	23.32%	3
2015 Q4	$16.5M	Buy	+522,500	New	+$18.5M	18.1%	3

Other funds holding MRTX

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Aviva Holdings's MRTX Position: Q4 2023 in Review

Aviva Holdings sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 3,135,966 shares — an estimated $137M sold.

Aviva Holdings first reported a position in MRTX in Q4 2015 and held it in 32 quarters. The position peaked at $689M in Q4 2020. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Aviva Holdings reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Aviva Holdings sold 3,135,966 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $137M.
Aviva Holdings first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 32 quarters.
Aviva Holdings's Mirati Therapeutics, Inc. Common Stock position peaked at $689M in Q4 2020.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Aviva Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.